Literature DB >> 27126331

Respiratory syncytial virus-associated hospitalizations over three consecutive seasons in children with congenital heart disease.

B Resch1,2, S Kurath-Koller3,4, J Hahn4, W Raith3, M Köstenberger5, A Gamillscheg5.   

Abstract

The purpose of this investigation was to analyze the burden of respiratory syncytial virus (RSV)-related hospitalizations in infants and children with congenital heart disease (CHD) over three consecutive RSV seasons. Retrospectively, all children with hemodynamically significant (HS-CHD) and not significant (HNS-CHD) CHD born between 2004 and 2008 at a tertiary care university hospital and identified by ICD-10 diagnoses were included. Data on RSV-related hospitalizations over the first three years of life covering at least three RSV seasons (November-April) were analyzed. The overall incidence of RSV-related hospitalization was 9.6 % (58/602), without a statistically significant difference between HS-CHD and HNS-CHD (7.3 % vs. 10.4 %; p = 0.258). Recommendation of palivizumab prophylaxis did not influence the RSV hospitalization rates between groups. Patients with HS-CHD and early surgery were significantly less often hospitalized due to RSV compared to those with delayed surgery (1.3 % vs. 14.3 %; p = 0.003). The median duration of hospitalization was 8.5 days (HS-CHD: 14 vs. HNS-CHD: 7 days; p = 0.003). Thirteen patients (22.4 %) were admitted to the intensive care unit (ICU), for a median of 10 days. The median age at admission was 2 months, with a significant difference between HS-CHD and HNS-CHD (6 vs. 2 months; p = 0.001). The majority (97 %) of RSV-related hospitalizations occurred before 12 months of age. Patients with HS-CHD had a significantly more severe course of RSV disease and were older at the time of hospitalization. Early surgery seemed to significantly reduce the risk of RSV hospitalization during the first RSV season.

Entities:  

Mesh:

Year:  2016        PMID: 27126331     DOI: 10.1007/s10096-016-2649-1

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  21 in total

1.  Chronic diseases, chromosomal abnormalities, and congenital malformations as risk factors for respiratory syncytial virus hospitalization: a population-based cohort study.

Authors:  Kim Kristensen; Thomas Hjuler; Henrik Ravn; Eric A F Simões; Lone G Stensballe
Journal:  Clin Infect Dis       Date:  2012-01-12       Impact factor: 9.079

2.  Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria.

Authors:  Bernhard Resch; Constanze Sommer; Mark J C Nuijten; Susanne Seidinger; Evelyn Walter; Vera Schoellbauer; Wilhelm D Mueller
Journal:  Pediatr Infect Dis J       Date:  2012-01       Impact factor: 2.129

3.  Low incidence of respiratory syncytial virus hospitalisations in haemodynamically significant congenital heart disease.

Authors:  A Duppenthaler; R A Ammann; M Gorgievski-Hrisoho; J-P Pfammatter; C Aebi
Journal:  Arch Dis Child       Date:  2004-10       Impact factor: 3.791

4.  Respiratory syncytial viral infection in infants with congenital heart disease.

Authors:  N E MacDonald; C B Hall; S C Suffin; C Alexson; P J Harris; J A Manning
Journal:  N Engl J Med       Date:  1982-08-12       Impact factor: 91.245

5.  Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. The Cardiac Study Group.

Authors:  E A Simoes; H M Sondheimer; F H Top; H C Meissner; R C Welliver; A A Kramer; J R Groothuis
Journal:  J Pediatr       Date:  1998-10       Impact factor: 4.406

6.  Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children. Pediatric Investigators Collaborative Network on Infections in Canada.

Authors:  L Navas; E Wang; V de Carvalho; J Robinson
Journal:  J Pediatr       Date:  1992-09       Impact factor: 4.406

Review 7.  The risk of mortality among young children hospitalized for severe respiratory syncytial virus infection.

Authors:  Shelagh M Szabo; Katherine L Gooch; Meagan M Bibby; Pamela G Vo; Ian Mitchell; Pamela Bradt; Adrian R Levy
Journal:  Paediatr Respir Rev       Date:  2013-01       Impact factor: 2.726

8.  Nosocomial infection: a risk factor for a complicated course in children with respiratory syncytial virus infection--results from a prospective multicenter German surveillance study.

Authors:  Arne Simon; Andreas Müller; Karun Khurana; Steffen Engelhart; Martin Exner; Oliver Schildgen; Anna M Eis-Hübinger; Wolfgang Kamin; Thomas Schaible; Karoline Wadas; Roland A Ammann; Anja Wilkesmann
Journal:  Int J Hyg Environ Health       Date:  2007-09-14       Impact factor: 5.840

9.  Risk factors for respiratory syncytial virus hospitalisation in children with heart disease.

Authors:  K Kristensen; L G Stensballe; J Bjerre; D Roth; N Fisker; T Kongstad; A L Svendsen; B W Nielsen
Journal:  Arch Dis Child       Date:  2009-06-18       Impact factor: 3.791

10.  Risk of Respiratory Syncytial Virus Infection in Cyanotic Congenital Heart Disease in a Subtropical Area.

Authors:  Shuenn-Nan Chiu; Pei-Lan Shao; Hui-Chi Chen; Ming-Tai Lin; Li-Min Huang; Feng-Yu Kao; San-Kuei Huang; Jou-Kou Wang; Mei-Hwan Wu
Journal:  J Pediatr       Date:  2016-01-25       Impact factor: 4.406

View more
  4 in total

Review 1.  Defining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Infants with Congenital Heart Disease.

Authors:  Paul A Checchia; Bosco Paes; Louis Bont; Paolo Manzoni; Eric A F Simões; Brigitte Fauroux; Josep Figueras-Aloy; Xavier Carbonell-Estrany
Journal:  Infect Dis Ther       Date:  2017-01-09

Review 2.  Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection.

Authors:  Bernhard Resch
Journal:  Hum Vaccin Immunother       Date:  2017-06-12       Impact factor: 3.452

3.  Emergency room endotracheal intubation in children with bronchiolitis: A cohort study using a multicenter database.

Authors:  Marla R Carter; Aamer H Khan; Tarek Salman; Richard Speicher; Alexandre T Rotta; Steven L Shein
Journal:  Health Sci Rep       Date:  2020-06-30

Review 4.  The Role of Clinical Virology Laboratory and the Clinical Virology Laboratorian in Ensuring Effective Surveillance for Influenza and Other Respiratory Viruses: Points to Consider and Pitfalls to Avoid.

Authors:  Steven J Drews
Journal:  Curr Treat Options Infect Dis       Date:  2016-07-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.